{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-173010","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.621753+00:00","generated_at":"2026-05-17T20:48:08.696703+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Shattuck Labs raises up to $103M in oversubscribed private placement to fund SL-325 Phase 2 trials","bullets":["Initial $46M gross proceeds from shares/pre-funded warrants; up to $57M additional if common warrants fully exercised.","OrbiMed led round; participation from Adage Capital, Redmile Group, Coastlands Capital, Prosight Capital, NextBio Capital.","Proceeds to fund SL-325 Phase 1 (start Q3 2025) and multiple Phase 2 trials including IBD; cash runway into 2029.","Common warrants ($1.0846 exercise) expire 30 days after public Phase 1 data announcement, expected in 2026.","Closing contingent on IND clearance for SL-325; certain investors receive board designation rights at closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-173010","json":"https://secwatch.observer/filing/0001193125-25-173010.json","markdown":"https://secwatch.observer/filing/0001193125-25-173010.md","text":"https://secwatch.observer/filing/0001193125-25-173010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000119312525173010/0001193125-25-173010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000119312525173010/d12427d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:48:08.696703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}